Organogenesis Holdings Inc. provided earnings guidance for the year ending December 31, 2022. For the year, the company expected net revenue of between $485 million and $515 million, representing an increase of approximately 4% to 10% year-over-year as compared to net revenue of $468.1 million for the year ended December 31, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.82 USD | +1.81% | -5.05% | -31.05% |
13/05 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
10/05 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.05% | 367M | |
+64.23% | 55.07B | |
-2.31% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+11.97% | 26.28B | |
-21.16% | 18.93B | |
+7.54% | 13.03B | |
+27.17% | 12.26B | |
+25.72% | 12.21B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022